Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GH — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

8.87

Margin Of Safety %

Put/Call OI Ratio

1.15

EPS Next Q Diff

0.13

EPS Last/This Y

1.87

EPS This/Next Y

1

Price

168.46

Target Price

198.17

Analyst Recom

1.46

Performance Q

Upside

-127.0%

Beta

1.57

Ticker: GH




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13GH158.40.831.1623685
2026-07-14GH160.140.840.1623920
2026-07-15GH163.010.820.3624172
2026-07-16GH155.090.810.4624506
2026-07-17GH156.350.800.2424925
2026-07-20GH148.050.893.4117290
2026-07-21GH152.260.871.7217328
2026-07-22GH150.750.860.9517560
2026-07-23GH150.280.855.6417495
2026-07-24GH147.360.860.8017626
2026-07-27GH144.830.860.8417653
2026-07-28GH143.510.820.7417608
2026-07-29GH144.10.828.0617668
2026-07-30GH152.531.151.0120822
2026-07-31GH161.841.150.8721453
2026-08-03GH160.071.160.4921930
2026-08-04GH159.861.150.3322018
2026-08-05GH163.121.160.8421977
2026-08-07GH168.581.150.5222550
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13GH158.6210.915.9-1.40
2026-07-14GH160.1111.18.1-1.40
2026-07-15GH162.9411.15.2-1.40
2026-07-16GH155.0011.132.5-1.40
2026-07-17GH155.8911.110.4-1.40
2026-07-20GH148.1911.132.5-1.40
2026-07-21GH152.2511.51.0-1.39
2026-07-22GH150.6411.517.0-1.39
2026-07-23GH150.2411.513.8-1.39
2026-07-24GH147.4611.519.9-1.39
2026-07-27GH145.5711.517.3-1.39
2026-07-28GH143.4811.518.3-1.39
2026-07-29GH144.2011.510.4-1.39
2026-07-30GH152.5311.5-11.3-1.39
2026-07-31GH161.8911.5-11.9-1.39
2026-08-03GH158.7811.539.7-1.39
2026-08-04GH158.7811.539.7-1.39
2026-08-05GH163.0921.7-9.6-1.43
2026-08-06GH157.5621.714.1-1.43
2026-08-07GH168.4622.6-31.0-1.45
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




2 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-08-06GH-12.67-0.138.87
2026-08-07GH-12.69-0.138.87
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2 items Current Page1 of 1

Last Quarter Act. EPS

-0.42

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

-0.29

Insider Transactions

-12.69

Institutional Transactions

-0.13

Beta

1.57

Average Sales Estimate Current Quarter

349

Average Sales Estimate Next Quarter

368

Fair Value

Quality Score

29

Growth Score

52

Sentiment Score

95

Actual DrawDown %

4.6

Max Drawdown 5-Year %

-87.8

Target Price

198.17

P/E

Forward P/E

PEG

P/S

19.11

P/B

P/Free Cash Flow

EPS

-3.5

Average EPS Est. Cur. Y​

-1.45

EPS Next Y. (Est.)

-0.45

Target Price Estimates Raised

2

Target Price Estimates Lowered

Profit Margin

-38.33

Relative Volume

0.8

Return on Equity vs Sector %

176.1

Return on Equity vs Industry %

192

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.05

EBIT Estimation

-31
GH Healthcare
$168.48
📉
Swing / Pullback
Buy the dip on strong trends
43 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
4/15
Valuation
4/20
TP/AR
5/10
Options
4/10
RSI
63.3
Range 1M
75.7%
Sup Dist
7.6%
🚀
Momentum Growth
Ride accelerating trends
34 /100
WEAK
Momentum
21/25
Growth
5/30
Estimates
5/20
Inst/Vol
0/15
Options
3/10
EPS Yr
3.9%
52W%
93.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +17.6% upside
Quality
7/30
Valuation
4/30
Growth
3/25
Stability
7/10
LT Trend
4/5
Upside
+17.6%
Quality
29
GH — P/E HistoricalDiagnostics & Research
Guardant Health, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2490
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
GH

Latest News

Caricamento notizie per GH
stock quote shares GH – Guardant Health, Inc. Stock Price stock today
news today GH – Guardant Health, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GH – Guardant Health, Inc. yahoo finance google finance
stock history GH – Guardant Health, Inc. invest stock market
stock prices GH premarket after hours
ticker GH fair value insiders trading